Press-release for stocks

Prices are updated after-hours

crawled time : 20:20 source : Www.globenewswire.com

save search

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
Published: 2024-04-07 (Crawled : 20:20) - globenewswire.com
ESPR | $1.93 -16.45% -19.69% 6.8M

Health Technology

| -37.78% | O: 9.32% H: 0.0% C: -10.88%
nexletol obesity

Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Published: 2024-04-07 (Crawled : 20:20) - globenewswire.com
SNYNF | $92.9 -2.18% 880

Health Technology

| 0.3% | O: 2.24% H: 0.0% C: -0.8%
SNY | $46.22 0.63% 0.63% 1.7M

Health Technology

| -1.46% | O: 0.84% H: 0.0% C: 0.0%
REGN | $898.33 -0.7% -0.71% 650K

Health Technology

| -4.22% | O: 0.11% H: 0.32% C: -0.07%
response

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
Published: 2024-04-07 (Crawled : 20:20) - globenewswire.com
BNTX | $87.88 1.62% 1.59% 750K

Health Technology

| -1.5% | O: 1.38% H: 0.2% C: -1.27%
candidate cancer pancreatic tumor immunotherapy for response show

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
Published: 2024-04-06 (Crawled : 20:20) - globenewswire.com
AMRN | $0.9225 -3.61% -3.74% 620K

Health Technology

| Email alert Add to watchlist
disease cardiovascular show

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
Published: 2024-04-06 (Crawled : 20:20) - globenewswire.com
NVSEF | $93.6375 6.88% 82K

Health Technology

| Email alert Add to watchlist
NVS | $94.41 0.95% 0.0% 1.4M

Health Technology

| Email alert Add to watchlist
leqvio novartis therapy show

Pineapple Energy to Release Fourth Quarter and Full Year 2023 Results, Host Conference Call on March 28
Published: 2024-03-23 (Crawled : 20:20) - globenewswire.com
PEGY | $0.0489 -7.39% -7.98% 3.9M

Manufacturing

| Email alert Add to watchlist
conference energy year

HII Celebrates 2023 Graduates of The Newport News Shipbuilding Apprentice School
Published: 2024-03-23 (Crawled : 20:20) - globenewswire.com
HII | $275.0 -0.26% 0.0% 340K

Electronic Technology

| Email alert Add to watchlist

HII’s Ingalls Shipbuilding Celebrates Apprentice Graduates
Published: 2024-03-16 (Crawled : 20:20) - globenewswire.com
HII | $275.0 -0.26% 0.0% 340K

Electronic Technology

| Email alert Add to watchlist

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
Published: 2024-03-10 (Crawled : 20:20) - globenewswire.com
ARQT A | $10.085 -1.13% -1.14% 2.7M

Health Technology

| -9.51% | O: 0.18% H: 3.39% C: -10.12%
children dermatitis meeting trial

Millicom (Tigo) share repurchase activity
Published: 2024-03-09 (Crawled : 20:20) - globenewswire.com
TIGO | $19.73 -1.74% -1.77% 45K

Communications

| Email alert Add to watchlist
repurchase

Tenaris to Commence a USD 300 million Second Tranche of its USD 1.2 Billion Share Buyback Program
Published: 2024-02-25 (Crawled : 20:20) - globenewswire.com
TNRSF | $19.97 -3.67% 260

Non-Energy Minerals

| Email alert Add to watchlist
TS | $38.2 -0.86% 0.0% 1.2M

Non-Energy Minerals

| Email alert Add to watchlist
million program

Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
Published: 2024-02-24 (Crawled : 20:20) - globenewswire.com
CLDX | $39.09 -0.41% -0.41% 410K

Health Technology

| Email alert Add to watchlist
urticaria positive week therapeutics results study

Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
Published: 2024-01-07 (Crawled : 20:20) - globenewswire.com
VINC | $0.8556 -12.69% -14.54% 1.2M

| -26.27% | O: 38.56% H: 4.59% C: -16.82%
pharma

Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance
Published: 2024-01-07 (Crawled : 20:20) - globenewswire.com
XGN | $1.46 -1.35% -1.37% 19K

Health Services

| Email alert Add to watchlist
results

QIAGEN announces plans to return approximately $300 million to shareholders
Published: 2024-01-07 (Crawled : 20:20) - globenewswire.com
QGEN | $39.67 -1.27% 0.0% 550K

Health Technology

| -10.14% | O: 1.25% H: 1.44% C: 1.39%
QGEN | $39.67 -1.27% 0.0% 550K

Health Technology

| -10.14% | O: 1.25% H: 1.44% C: 1.39%
million

Passing of Gustavo Cisneros
Published: 2023-12-30 (Crawled : 20:20) - globenewswire.com
GOLD | $17.37 -2.74% 0.12% 33M

Non-Energy Minerals

| Email alert Add to watchlist
GOLD | $17.37 -2.74% 0.09% 33M

Non-Energy Minerals

| Email alert Add to watchlist

Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
Published: 2023-12-10 (Crawled : 20:20) - globenewswire.com
SNY | $46.22 0.63% 0.63% 1.7M

Health Technology

| Email alert Add to watchlist
SNYNF | $92.9 -2.18% 880

Health Technology

| Email alert Add to watchlist
REGN | $898.33 -0.7% -0.71% 650K

Health Technology

| Email alert Add to watchlist
trial potential

Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023
Published: 2023-12-10 (Crawled : 20:20) - globenewswire.com
VINC | $0.8556 -12.69% -14.54% 1.2M